PMID- 28539618
OWN - NLM
STAT- MEDLINE
DCOM- 20181214
LR  - 20221207
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 7
IP  - 1
DP  - 2017 May 24
TI  - Effect of exenatide after short-time intensive insulin therapy on glycaemic 
      remission maintenance in type 2 diabetes patients: a randomized controlled trial.
PG  - 2383
LID - 10.1038/s41598-017-02631-1 [doi]
LID - 2383
AB  - Early short-term intensive insulin (STII) therapy can induce drug-free glycemic 
      remission for up to 1 year in half of newly diagnosed type 2 diabetic mellitus 
      (T2DM) patients. Whether exenatide following STII therapy will induce higher 
      long-term glycaemic remission is currently unknown. To assess the effect of STII+ 
      exenatide therapy, compared with STII only, on maintenance of glycaemic remission 
      in newly diagnosed T2DM patients. In this randomized, parallel-group, open-label, 
      controlled trial, 129 patients (66 in STII+ exenatide group and 63 in STII only 
      group) firstly completed 3-week STII therapy, then STII+ exenatide group was 
      treated with exenatide for 12 weeks further. The cumulative probabilities of 
      1-year and 2-year glycaemic remission in STII+ exenatide group were 68.2 +/- 5.7% 
      and 53.0 +/- 6.1%, which were significantly higher than STII only group 
      (36.5 +/- 6.1% and 31.8 +/- 5.9%) (p-values < 0.001). Patients in STII+ exenatide 
      group, compared with STII only group, showed significantly decreased levels of 
      waist (82.2 (81.0, 83.5) cm v.s. 84.2 (82.7, 85.7) cm, p = 0.048) and HbA1c (5.83 
      (5.60, 6.06)% v.s. 6.49 (6.20, 6.77)%, p < 0.001) after 12-week exenatide 
      treatment, but these differences disappeared after 1-year and 2-year follow-up. 
      As conclusions, Improved effect of sequential exenatide after STII therapy on 
      maintenance of glycaemic remission only occurred during exenatide treatment and 
      lost upon treatment cessation.
FAU - Shi, Xiulin
AU  - Shi X
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Shi, Yalin
AU  - Shi Y
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
AD  - School of Medicine, Xiamen University, Xiamen, China.
FAU - Chen, Ning
AU  - Chen N
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Lin, Mingzhu
AU  - Lin M
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Su, Weijuan
AU  - Su W
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Zhang, Huijie
AU  - Zhang H
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Liu, Changqin
AU  - Liu C
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Song, Haiqu
AU  - Song H
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Xiao, Fangsen
AU  - Xiao F
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Huang, Peiying
AU  - Huang P
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Wang, Liying
AU  - Wang L
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Zeng, Jinyang
AU  - Zeng J
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
FAU - Yan, Bing
AU  - Yan B
AD  - Xiamen Diabetes Institute, Xiamen, China.
FAU - Liu, Qi
AU  - Liu Q
AD  - School of Medicine, Xiamen University, Xiamen, China.
FAU - Liu, Suhuan
AU  - Liu S
AD  - Xiamen Diabetes Institute, Xiamen, China.
FAU - Yang, Shuyu
AU  - Yang S
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
AD  - Xiamen Diabetes Institute, Xiamen, China.
FAU - Li, Xiaoying
AU  - Li X
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China.
AD  - Xiamen Diabetes Institute, Xiamen, China.
AD  - Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Li, Zhibin
AU  - Li Z
AD  - Xiamen Diabetes Institute, Xiamen, China. zhibinli33@hotmail.com.
AD  - Epidemiology Research Unit, The First Affiliated Hospital, Xiamen University, 
      Xiamen, China. zhibinli33@hotmail.com.
FAU - Li, Xuejun
AU  - Li X
AD  - Department of Endocrinology and Diabetes, The First Affiliated Hospital, Xiamen 
      University, Xiamen, China. xmlixuejun@163.com.
AD  - Xiamen Diabetes Institute, Xiamen, China. xmlixuejun@163.com.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20170524
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 9P1872D4OL (Exenatide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology
MH  - Exenatide/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Remission Induction
MH  - Time Factors
MH  - Waist Circumference/drug effects
PMC - PMC5443840
COIS- The authors declare that they have no competing interests.
EDAT- 2017/05/26 06:00
MHDA- 2018/12/15 06:00
PMCR- 2017/05/24
CRDT- 2017/05/26 06:00
PHST- 2016/11/29 00:00 [received]
PHST- 2017/04/13 00:00 [accepted]
PHST- 2017/05/26 06:00 [entrez]
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2018/12/15 06:00 [medline]
PHST- 2017/05/24 00:00 [pmc-release]
AID - 10.1038/s41598-017-02631-1 [pii]
AID - 2631 [pii]
AID - 10.1038/s41598-017-02631-1 [doi]
PST - epublish
SO  - Sci Rep. 2017 May 24;7(1):2383. doi: 10.1038/s41598-017-02631-1.